{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:48:35Z","timestamp":1793213315125,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41375-025-02854-6","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T10:44:13Z","timestamp":1767782653000},"page":"373-382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5406-9300","authenticated-orcid":false,"given":"Ayumi","family":"Fujimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-3179","authenticated-orcid":false,"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2682-2179","authenticated-orcid":false,"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Hiramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1884-4757","authenticated-orcid":false,"given":"Takuya","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikue","family":"Shiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0525-7636","authenticated-orcid":false,"given":"Fumihiro","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5974-7614","authenticated-orcid":false,"given":"Ritsuro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"2854_CR1","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.V67.4.925.925","volume":"67","author":"LA Fernandez","year":"1986","unstructured":"Fernandez LA, Pope B, Lee C, Zayed E. Aggressive natural killer cell leukemia in an adult with establishment of an NK cell line. Blood. 1986;67:925\u201330.","journal-title":"Blood"},{"key":"2854_CR2","unstructured":"Chan JKCWK, Jaffe ES, and Ralfkiaer E Aggressive NK-cell leukaemia. In Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France. IARC Press 2001:198\u2013200."},{"key":"2854_CR3","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/sj.leu.2403262","volume":"18","author":"R Suzuki","year":"2004","unstructured":"Suzuki R, Suzumiya J, Nakamura S, Aoki S, Notoya A, Ozaki S, et al. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia. 2004;18:763\u201370.","journal-title":"Leukemia"},{"key":"2854_CR4","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1349-7006.2012.02251.x","volume":"103","author":"F Ishida","year":"2012","unstructured":"Ishida F, Ko YH, Kim WS, Suzumiya J, Isobe Y, Oshimi K, et al. Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation. Cancer Sci. 2012;103:1079\u201383.","journal-title":"Cancer Sci"},{"key":"2854_CR5","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1002\/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1","volume":"76","author":"M Yamaguchi","year":"1995","unstructured":"Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, et al. Frequent expression of P-glycoprotein\/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76:2351\u20136.","journal-title":"Cancer"},{"key":"2854_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1182\/blood.V93.2.599","volume":"93","author":"M Egashira","year":"1999","unstructured":"Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood. 1999;93:599\u2013606.","journal-title":"Blood"},{"key":"2854_CR7","first-page":"1343","volume":"87","author":"SY Song","year":"2002","unstructured":"Song SY, Kim WS, Ko YH, Kim K, Lee MH, Park K. Aggressive natural killer cell leukemia: clinical features and treatment outcome. Haematologica. 2002;87:1343\u20135.","journal-title":"Haematologica"},{"key":"2854_CR8","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","volume":"29","author":"M Yamaguchi","year":"2011","unstructured":"Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29:4410\u20136.","journal-title":"J Clin Oncol"},{"key":"2854_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13045-016-0271-4","volume":"9","author":"KS Jung","year":"2016","unstructured":"Jung KS, Cho SH, Kim SJ, Ko YH, Kang ES, Kim WS. L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia. J Hematol Oncol. 2016;9:41.","journal-title":"J Hematol Oncol"},{"key":"2854_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0021-z","volume":"7","author":"YT Tang","year":"2017","unstructured":"Tang YT, Wang D, Luo H, Xiao M, Zhou HS, Liu D, et al. Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes. Blood Cancer J. 2017;7:660.","journal-title":"Blood Cancer J"},{"key":"2854_CR11","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.bbmt.2017.01.082","volume":"23","author":"M Hamadani","year":"2017","unstructured":"Hamadani M, Kanate AS, DiGilio A, Ahn KW, Smith SM, Lee JW, et al. Allogeneic hematopoietic cell transplantation for aggressive NK cell leukemia. A center for international blood and marrow transplant research analysis. Biol Blood Marrow Transpl. 2017;23:853\u20136.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2854_CR12","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1016\/j.bbmt.2018.07.034","volume":"24","author":"SH Jeong","year":"2018","unstructured":"Jeong SH, Song HN, Park JS, Yang DH, Koh Y, Yoon SS, et al. Allogeneic stem cell transplantation for patients with natural killer\/T cell lymphoid malignancy: a multicenter analysis comparing upfront and salvage transplantation. Biol Blood Marrow Transpl. 2018;24:2471\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2854_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05651.x","volume":"130","author":"N Murashige","year":"2005","unstructured":"Murashige N, Kami M, Kishi Y, Kim SW, Takeuchi M, Matsue K, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol. 2005;130:561\u20137.","journal-title":"Br J Haematol"},{"key":"2854_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1600-0609.2008.01090.x","volume":"81","author":"T Ito","year":"2008","unstructured":"Ito T, Makishima H, Nakazawa H, Kobayashi H, Shimodaira S, Nakazawa Y, et al. Promising approach for aggressive NK cell leukaemia with allogeneic haematopoietic cell transplantation. Eur J Haematol. 2008;81:107\u201311.","journal-title":"Eur J Haematol"},{"key":"2854_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41409-020-01009-8","volume":"56","author":"A Fujimoto","year":"2021","unstructured":"Fujimoto A, Ishida F, Izutsu K, Yamasaki S, Chihara D, Suzumiya J, et al. Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia. Bone Marrow Transplant. 2021;56:347\u201356.","journal-title":"Bone Marrow Transplant"},{"key":"2854_CR16","unstructured":"Chan JKC JE, Ralfkiaer E, and Ko YH. Aggressive NK-cell leukaemia. In Swerdlow SH, Campo E, Harris NL, et al.(eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France. IARC Press 2008:276-7."},{"key":"2854_CR17","unstructured":"Chan JKC JE, and Ko YH. Aggressive NK-cell leukaemia. In Swerdlow SH, Campo E, Harris NL, et al.(eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France. IARC Press 2017:353-4."},{"key":"2854_CR18","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"2854_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"2854_CR20","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1532\/IJH97.03147","volume":"81","author":"M Mori","year":"2005","unstructured":"Mori M, Kitamura K, Masuda M, Hotta T, Miyazaki T, Miura AB, et al. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin\u2019s lymphoma. Int J Hematol. 2005;81:246\u201354.","journal-title":"Int J Hematol"},{"key":"2854_CR21","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/cncr.20999","volume":"103","author":"MP Escal\u00f3n","year":"2005","unstructured":"Escal\u00f3n MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer. 2005;103:2091\u20138.","journal-title":"Cancer"},{"key":"2854_CR22","first-page":"66","volume":"7","author":"A Fujimoto","year":"2021","unstructured":"Fujimoto A, Suzuki R. Progress in the treatment of NK-cell lymphoma\/leukemia. J Cancer Metastasis Treat. 2021;7:66.","journal-title":"J Cancer Metastasis Treat"},{"key":"2854_CR23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3389\/fped.2018.00292","volume":"6","author":"F Ishida","year":"2018","unstructured":"Ishida F. Aggressive NK-cell leukemia. Front Pediatr. 2018;6:292.","journal-title":"Front Pediatr"},{"key":"2854_CR24","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","volume":"117","author":"A Jaccard","year":"2011","unstructured":"Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study. Blood. 2011;117:1834\u20139.","journal-title":"Blood"},{"key":"2854_CR25","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41375-025-02527-4","volume":"39","author":"A Fujimoto","year":"2025","unstructured":"Fujimoto A, Miyazaki K, Yakushijin K, Fujino T, Munakata W, Ejima Y, et al. Improved prognosis of advanced-stage extranodal NK\/T-cell lymphoma: results of the NKEA-Next study. Leukemia. 2025;39:909\u201316.","journal-title":"Leukemia"},{"key":"2854_CR26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s12072-019-09971-2","volume":"13","author":"N Kamal","year":"2019","unstructured":"Kamal N, Koh C, Samala N, Fontana RJ, Stolz A, Durazo F, et al. Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis. Hepatol Int. 2019;13:641\u20138.","journal-title":"Hepatol Int"},{"key":"2854_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70184","volume":"9","author":"P Berning","year":"2025","unstructured":"Berning P, Ngoya M, Kim WS, Shumilov E, Wu D, Huang H, et al. Autologous stem cell transplantation in NK\/T-cell lymphoma: Prognostic impact of EBV-DNA in a multinational cohort-A study by the EBMT Lymphoma Working Party. Hemasphere. 2025;9:e70184.","journal-title":"Hemasphere"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02854-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02854-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02854-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:56:04Z","timestamp":1770274564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02854-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2854"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02854-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AF received honoraria from Chugai Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., and Abbvie GK, outside of the submitted work. T Maeda received honoraria from Bristol-Myers Squibb KK, Chugai Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Company Limited, AstraZeneca KK, Abbvie GK, Genmab A\/S, Pfizer Japan Inc., Asahi Kasei Pharma Corporation, Alexion Pharmaceuticals, Inc., Argenx Japan K.K., Eisai Co., Ltd., Fujimoto Pharmaceutical Corporation, Meiji Seika Pharma Co., Ltd., and BeiGene Ltd., outside of the submitted work. ND received consulting fees from Janssen Pharmaceutical K.K., and received honoraria from Nippon Shinyaku Co., Ltd., Janssen Pharmaceutical K.K., Novartis Pharma K.K., Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., Abbvie GK, AstraZeneca K.K., Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Asahi Kasei Pharma Corporation, Shionogi & Co., Ltd., Sanofi K.K., Merck & Co., Inc., Pfizer Japan Inc., and Takeda Pharmaceutical Company Limited, outside of the submitted work. NF received research grants from Abbvie GK, Chugai Pharmaceutical Co., Ltd., Chordia therapeutics Inc., Genmab A\/S, Haihe Biopharma Co., Ltd., Incyte Corporation, Kyowa Kirin Co., Ltd., Loxo Oncology Inc., Ono Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited, and received honoraria from Abbvie GK, AstraZeneca K.K., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Eisai Co., Ltd., Eli Lilly and Company, Genmab A\/S, Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Sanofi K.K., SymBio Pharmaceuticals Limited, and Takeda Pharmaceutical Company Limited, outside of the submitted work. H.G. received research grants from Gilead Sciences Inc. and Kyowa Kirin Co., Ltd., and received honoraria from Kyowa Kirin Co., Ltd., Bristol-Myers Squibb K.K., Abbvie GK, Genmab A\/S, Gilead Sciences Inc., Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K., Takeda Pharmaceutical Company Limited, and Janssen Pharmaceutical K.K., outside of the submitted work. T Miyazaki received honoraria from Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Novartis Pharma K.K., Astellas Pharma Inc., Meiji Seika Pharma Co., Ltd., and Arkray Inc., outside of the submitted work. KM received research grants from Takeda Pharmaceutical Company Limited, Otsuka Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Sumitomo Pharma Co., Ltd., and Zenyaku Kogyo Co., Ltd., and received honoraria from Chugai Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., AstraZeneca K.K., Novartis Pharma K.K., Incyte Corporation, Eisai Co., Ltd., Asahi Kasei Pharma Corporation, Abbvie GK, SymBio Pharmaceuticals Limited, Ono Pharmaceutical Co., Ltd., Genmab A\/S, Meiji Seika Pharma Co., Ltd., Bristol-Myers Squibb K.K., Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., Gilead Sciences Inc., and Nippon Shinyaku Co., Ltd., outside of the submitted work. M.Y. received research grants from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Genmab A\/S, Incyte Corporation, Abbvie GK, and SymBio Pharmaceuticals Limited, received consulting fees from Genmab A\/S, BeiGene Ltd., Nihon Servier Co. Ltd., Daiichi Sankyo Co., Ltd., SymBio Pharmaceuticals Limited, and Nippon Medac Co., Ltd., and received honoraria from Abbvie GK, Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Genmab A\/S, Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Meiji Seika Pharma Co., Ltd., Merck & Co., Inc., Ono Pharmaceutical Co., Ltd., SymBio Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., and Nihon Servier Co. Ltd., outside of the submitted work. F.I. received research grants from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Hokuto Japan Co., Ltd., and CSL Behring K.K., received consulting fees from Kissei Pharmaceutical Co., Ltd., and received honoraria from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., PharmaEssentia Japan K.K., Ono Pharmaceutical Co., Ltd., and Eisai Co., Ltd., outside of the submitted work. RS received research grants from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eisai Co., Ltd., Meiji Seika Pharma Co., Ltd., and Otsuka Pharmaceutical Co., Ltd., and received honoraria from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Abbvie GK, Bristol-Myers Squibb K.K., Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Company Limited, Meiji Seika Pharma Co., Ltd., Novartis Pharma K.K., SymBio Pharmaceuticals Limited, Astellas Pharma Inc., Nihon Servier Co. Ltd., Asahi Kasei Pharma Corporation, Pfizer Japan Inc., and AstraZeneca K.K., outside of the submitted work. The other authors have no financial conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the ethical committee of Shimane University (approval number: KS20211027-1) as well as the institutional review boards of all participating institutes. All procedures were performed in accordance with the Japanese Ethical Guidelines for Medical and Biological Research Involving Human Subjects. Informed consent was obtained using an opt-out method due to the retrospective nature of this study, in compliance with Japanese guidelines and regulations. Details of this study were publicly disclosed on the websites of all participating institutes, thereby providing patients with the opportunity to decline participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}